G&A is now $8.2 million/year. Does that seem a tad high?
R&D is listed as "(net)". What does that mean? Have they backed out the French credit?
Does anyone have a reference for the French R&D rebate? And how much of total R&D is eligible?
- Forums
- ASX - By Stock
- WBT
- Ann: H1 FY22 Results Release
Ann: H1 FY22 Results Release, page-29
Featured News
Add WBT (ASX) to my watchlist
(20min delay)
|
|||||
Last
$3.21 |
Change
0.480(17.6%) |
Mkt cap ! $564.0M |
Open | High | Low | Value | Volume |
$2.80 | $3.30 | $2.80 | $3.622M | 1.192M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 4089 | $3.19 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$3.22 | 4568 | 6 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 3333 | 3.190 |
4 | 3518 | 3.180 |
2 | 1686 | 3.170 |
3 | 2041 | 3.160 |
2 | 1174 | 3.150 |
Price($) | Vol. | No. |
---|---|---|
3.200 | 365 | 1 |
3.210 | 3520 | 4 |
3.220 | 1738 | 3 |
3.230 | 412 | 1 |
3.240 | 2063 | 3 |
Last trade - 12.00pm 12/11/2024 (20 minute delay) ? |
Featured News
WBT (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Michael Thurn, CEO & MD
Michael Thurn
CEO & MD
Previous Video
Next Video
SPONSORED BY The Market Online